1. Home
  2. PSTL vs ADCT Comparison

PSTL vs ADCT Comparison

Compare PSTL & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Postal Realty Trust Inc.

PSTL

Postal Realty Trust Inc.

HOLD

Current Price

$21.22

Market Cap

554.6M

Sector

Real Estate

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$3.78

Market Cap

484.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSTL
ADCT
Founded
N/A
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
554.6M
484.4M
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
PSTL
ADCT
Price
$21.22
$3.78
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$20.19
$7.75
AVG Volume (30 Days)
194.1K
891.7K
Earning Date
05-05-2026
05-04-2026
Dividend Yield
4.54%
N/A
EPS Growth
123.81
30.86
EPS
0.47
N/A
Revenue
$95,823,000.00
$81,357,000.00
Revenue This Year
$18.01
N/A
Revenue Next Year
$11.38
$66.49
P/E Ratio
$46.09
N/A
Revenue Growth
25.47
14.85
52 Week Low
$12.26
$1.23
52 Week High
$21.95
$4.98

Technical Indicators

Market Signals
Indicator
PSTL
ADCT
Relative Strength Index (RSI) 61.51 42.38
Support Level $18.24 $3.65
Resistance Level N/A $3.88
Average True Range (ATR) 0.43 0.23
MACD 0.10 -0.03
Stochastic Oscillator 69.69 9.96

Price Performance

Historical Comparison
PSTL
ADCT

About PSTL Postal Realty Trust Inc.

Postal Realty Trust Inc is an internally managed real estate investment trust. It is engaged in acquiring and managing properties mainly leased to the United States Postal Service, or the USPS, ranging from last-mile post offices to industrial facilities. The Trust's objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of its revenue is generated in the form of rental income.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: